Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.53 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.50 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479082 | 0.91 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5474647 | 0.91 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5474147 | 0.90 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5478982 | 0.90 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5474139 | 0.88 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5470598 | 0.88 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5474610 | 0.88 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5470576 | 0.86 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5474148 | 0.85 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5482197 | 0.83 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-11 | — | — | US | claimed |
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | MAPK1, NOS1, NOS2 | MAPK14 12/4885MAPK13 5/4885MAPK12 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.